Targeting Metabolic Reprogramming for the Prevention and Treatment of Proliferative Vitreoretinopathy
Abstract
This is our third year on the project, and we have continued to publish our new findings identifying the key metabolic reprogramming traits associated with proliferative vitreoretinopathy (PVR) using our in-vitro model of epithelial-mesenchymal transition (EMT) and inflammation of human retinal pigment epithelial cells (RPE). Our research findings have yielded the identification of several promising metabolic drugs which effectively block retinal EMT in vitro to be tested in our in vivo rabbit ocular surgery model of PVR. We have now collected a total of 43 human vitreous samples. We have sent through primary human RPE cells for metabolomics processing and will compare these results with our ARPE-19 cell line data. We have identified another cytokine that induces EMT of RPE, namely, tumor necrosis factor-alpha, and found that it exerts opposite effects to metabolic reprogramming compared to transforming growth factor-beta and found a novel metabolic drug, dimethyl fumarate (DMFu) that blocks to activity of tumor necrosis factor-alpha.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1192629
Entities
People
- Daisy Y Shu
- Leo Kim
Organizations
- Schepens Eye Research Institute